StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix operating margin

Operating margin is operating income as a percentage of revenue.

Ocular Therapeutix's operating margin for the twelve months ending Jun 30, 2026 was -603.0%. For fiscal 2025 it was -519.8%, against -269.6% the year before. The highest annual figure on record is -141.0% in fiscal 2023.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-519.8%−250.2
FY2024Dec 31, 2024-269.6%−128.6
FY2023Dec 31, 2023-141.0%+11.8
FY2022Dec 31, 2022-152.7%+26.6
FY2021Dec 31, 2021-179.3%+181.8
FY2020Dec 31, 2020-361.1%+1668.7
FY2019Dec 31, 2019-2029.9%+940.9
FY2018Dec 31, 2018-2970.8%+249.4
FY2017Dec 31, 2017-3220.1%−924.1
FY2016Dec 31, 2016-2296.0%−113.3
FY2015Dec 31, 2015-2182.7%+1326.9
FY2014Dec 31, 2014-3509.6%+133200.4
FY2012Dec 31, 2012-136710.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-609.3%−106.8
Q1 FY2026Mar 31, 2026-865.5%−268.0
Q4 FY2025Dec 31, 2025-526.5%−230.4
Q3 FY2025Sep 30, 2025-472.3%−174.1
Q2 FY2025Jun 30, 2025-502.6%−237.4
Q1 FY2025Mar 31, 2025-597.5%−383.5
Q4 FY2024Dec 31, 2024-296.1%−160.6
Q3 FY2024Sep 30, 2024-298.2%−170.8
Q2 FY2024Jun 30, 2024-265.1%−129.7
Q1 FY2024Mar 31, 2024-214.0%−45.4
Q4 FY2023Dec 31, 2023-135.5%+2.1
Q3 FY2023Sep 30, 2023-127.4%+52.7
Q2 FY2023Jun 30, 2023-135.5%+26.9
Q1 FY2023Mar 31, 2023-168.6%−33.4
Q4 FY2022Dec 31, 2022-137.6%+9.1
Q3 FY2022Sep 30, 2022-180.1%−19.4
Q2 FY2022Jun 30, 2022-162.4%+10.3
Q1 FY2022Mar 31, 2022-135.2%+140.3
Q4 FY2021Dec 31, 2021-146.6%+48.5
Q3 FY2021Sep 30, 2021-160.7%+77.7
Q2 FY2021Jun 30, 2021-172.6%+967.2
Q1 FY2021Mar 31, 2021-275.5%+361.3
Q4 FY2020Dec 31, 2020-195.2%+753.5
Q3 FY2020Sep 30, 2020-238.4%+2553.4
Q2 FY2020Jun 30, 2020-1139.8%+2183.1
Q1 FY2020Mar 31, 2020-636.8%+3358.7
Q4 FY2019Dec 31, 2019-948.6%+2480.5
Q3 FY2019Sep 30, 2019-2791.8%+183.3
Q2 FY2019Jun 30, 2019-3322.9%−1229.7
Q1 FY2019Mar 31, 2019-3995.5%−38.2
Q4 FY2018Dec 31, 2018-3429.2%−818.1
Q3 FY2018Sep 30, 2018-2975.1%−69.6
Q2 FY2018Jun 30, 2018-2093.2%+2093.8
Q1 FY2018Mar 31, 2018-3957.4%−658.0
Q4 FY2017Dec 31, 2017-2611.1%−170.4
Q3 FY2017Sep 30, 2017-2905.5%−968.9
Q2 FY2017Jun 30, 2017-4187.0%–
Q1 FY2017Mar 31, 2017-3299.4%–
Q4 FY2016Dec 31, 2016-2440.7%–
Q3 FY2016Sep 30, 2016-1936.7%–

More Ocular Therapeutix figures

See a number that looks wrong?